USE OF COMPOUNDS ISOLATED FROM MORUS BARK

PURPOSE: A final glycosylation product inhibitor or health functional food is provided to suppress development of diabetic complication. CONSTITUTION: A final glycosylation product inhibitor which suppresses the development of diabetes complication contains mulberrofuran G isolated from Morus bark,...

Full description

Saved in:
Bibliographic Details
Main Authors CHANG, HWAN BONG, YOON, JOO BYOUNG, LEE, HYUN YONG, CHOI, HYUN SIK, LEE, HYUNG BOK
Format Patent
LanguageEnglish
Korean
Published 11.10.2012
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PURPOSE: A final glycosylation product inhibitor or health functional food is provided to suppress development of diabetic complication. CONSTITUTION: A final glycosylation product inhibitor which suppresses the development of diabetes complication contains mulberrofuran G isolated from Morus bark, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2',4',5,7-tetrahydroxyflavanone, morusignin L, or dihydromorin as an active ingredient. The diabetic complication includes diabetic splenocyte nephritis, diabetic retinopathy or diabetic splenocyte neuropathic disease. [Reference numerals] (1) Normal group(-20°C); (10) Morusignin-L; (11) Dihydromorin; (2) Control group(37°C); (3) Pyridoxamine(positive control group); (4) Mulberrofuran-G; (5) Mulberrofuran-K; (6) Kuwanon-G; (7) Kuwanon-Z; (8) 2'.4'.5.7-tetrahydroxyflavanone; (9) Oxyresveratrol; (AA) Anti-AGEs antibody; (BB) Anti-CML antibody; (CC) Ponseau S staining
Bibliography:Application Number: KR20110027789